2020
Risk associated alterations in marrow T cells in pediatric leukemia
Bailur JK, McCachren SS, Pendleton K, Vasquez JC, Lim H, Duffy A, Doxie D, Kaushal A, Foster C, DeRyckere D, Castellino S, Kemp ML, Qiu P, Dhodapkar M, Dhodapkar K. Risk associated alterations in marrow T cells in pediatric leukemia. JCI Insight 2020, 5: e140179. PMID: 32692727, PMCID: PMC7455136, DOI: 10.1172/jci.insight.140179.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBone MarrowCase-Control StudiesChildChild, PreschoolFemaleGene Expression ProfilingHumansInfantKiller Cells, NaturalLeukemia, Myeloid, AcuteMalePrecursor Cell Lymphoblastic Leukemia-LymphomaReproducibility of ResultsRisk FactorsSingle-Cell AnalysisT-LymphocytesTumor MicroenvironmentConceptsAcute lymphoblastic leukemiaNaive T cellsT cellsDisease riskChildhood leukemiaLymphoblastic leukemiaStem-like memory T cellsTerminal effector T cellsB-cell acute lymphoblastic leukemiaChronic immune activationCell acute lymphoblastic leukemiaEffector T cellsMarrow T cellsMemory T cellsAcute myelogenous leukemiaEvidence of dysfunctionStem-like genesImmune signaturesNK cellsClinical featuresImmune environmentImmune landscapeImmune therapyImmune activationImmune microenvironment
2015
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 2015, 125: 4042-4051. PMID: 25869284, PMCID: PMC4481593, DOI: 10.1182/blood-2014-11-611426.Peer-Reviewed Original ResearchConceptsImmune activationAntitumor effectsNK cellsT cellsMore frequent adverse eventsClinical antitumor effectsFrequent adverse eventsNatural killer cellsIntermittent dosing strategyDirect antitumor effectsExpression of cytokinesT cell activationGreater tumor reductionPomalidomide/Coinhibitory receptorsAdverse eventsClinical responseOverall survivalKiller cellsPharmacodynamic effectsImmunomodulatory effectsMultiple myelomaTumor reductionIntermittent dosingPharmacodynamic analysis